A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia
KO-MEN-008
Phase 1 other active
Quick answer
A Study to Investigate the Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia for Relapsed and/or refractory Acute Myeloid Leukemia is a Phase 1 program (other) at Kura Oncology with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Kura Oncology
- Indication
- Relapsed and/or refractory Acute Myeloid Leukemia
- Phase
- Phase 1
- Modality
- other
- Status
- active